Objective:

To evaluate the effects of dapagliflozin on myocardial motion parameters and cardiac electrophysiology in patients with T2DM and CHD, focusing on primary outcomes such as left ventricular ejection fraction and exercise tolerance.

Key Findings:

• Dapagliflozin group showed superior clinical efficacy (93.60% vs. 76.64%, P < 0.001), measured by improvements in key cardiac metrics.
• Greater improvements in left ventricular ejection fraction, myocardial strain and work indices, and exercise tolerance (all P < 0.01).
• Enhanced cardiac electrophysiological activity, including longer QT and Tp-Te intervals and reduced ST depression (all P < 0.01).
• No significant difference in adverse event rates between groups.

Interpretation:

Dapagliflozin improves cardiac function, myocardial performance, electrophysiological parameters, and exercise tolerance in patients with T2DM and CHD, suggesting its potential role in clinical management without increasing adverse cardiovascular events.

Limitations:

• Retrospective design may introduce bias.
• Short treatment duration may limit long-term applicability of findings, and lack of long-term follow-up data.

Conclusion:

Adding dapagliflozin to conventional therapy improves cardiac outcomes in patients with T2DM and CHD.